DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Quizartinib
Quizartinib
FLT3 Inhibitors in Acute Myeloid Leukemia Mei Wu1, Chuntuan Li2 and Xiongpeng Zhu2*
Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling While Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
Letters to the Editor
Isoliquiritigenin, an Orally Available Natural FLT3 Inhibitor from Licorice, Exhibits Selective Anti–Acute Myeloid Leukemia Efficacy in Vitro and in Vivo
The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis Tsapogas, Panagiotis; Mooney, Ciaran; Brown, Geoffrey; Rolink, Antonius
Crenolanib Is a Selective Type I Pan-FLT3 Inhibitor
A Phase 1/2 Study of the Oral FLT3 Inhibitor Pexidartinib in Relapsed/Refractory FLT3-ITD-Mutant Acute Myeloid Leukemia
JULY 2019 Mrx Pipeline a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
FLT3 Inhibitor, with Azacitidine (AZA) Or Low-Dose Cytarabine (LDAC) Might Improve the Outcomes in Patients with FLT3- ITD-Mutated AML
Clinical Benefits and Safety of FMS-Like Tyrosine Kinase 3
New Directions for Emerging Therapies in Acute Myeloid Leukemia: the Next Chapter Naval Daver 1,Andrewh.Wei2, Daniel A
Rare Diseases, When Taken Together, Are Are Together, When Taken Diseases, Rare to According at All
Acute Myeloid Leukemia
Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
An Open-Label Study of Quizartinib Monotherapy Vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects
Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives
Specialty Pipeline Monthly Update
+ Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling
Top View
Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: the Path to Least Resistance
Tyrosine Kinase Inhibition Increases the Cell Surface Localization of FLT3-ITD and Enhances FLT3-Directed Immunotherapy of Acute Myeloid Leukemia
LEE-DISSERTATION-2019.Pdf
Haematologica.Org/Content/104/10/2017 Tinib Through Combined Upregulation of AXL Activity
Quizartinib, a Selective FLT3 Inhibitor, Maintains Antileukemic Activity in Preclinical Models of RAS-Mediated Midostaurin- Resistant Acute Myeloid Leukemia Cells
Acute Myeloid Leukemia
FLT3 Signalling Pathways in Acute Myeloid Leukaemia
Quizartinib for Treating Relapsed Or Refractory Acute Myeloid Leukaemia
HOPA News Volume 10, Issue 1
November 2018
Outcomes with Sequential FLT3-Inhibitor-Based Therapies In
Targeting the FMS-Like Tyrosine Kinase 3 in Acute Myeloid Leukemia
Nuclear Factor of Activated T-Cells, NFATC1, Governs FLT3ITD-Driven Hematopoietic Stem Cell Transformation and a Poor Prognosis
CBL Family E3 Ubiquitin Ligases Control JAK2 Ubiquitination and Stability in Hematopoietic Stem Cells and Myeloid Malignancies
211349Orig1s000
Recent Advances in the Cellular and Molecular Understanding of Myelodysplastic Syndromes: Implications for New Therapeutic Approaches
Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments
Final Scope PDF 218 KB